Biotech EyeGate Pharmaceuticals files for a $29 million IPO

By
A A A

EyeGate Pharmaceuticals, a late-stage biotech developing a therapy for eye inflammation, filed on Wednesday with the SEC to raise up to $29 million in an initial public offering. The company has completed a Phase 3 trial for its combined inflammation treatment and novel delivery system.

Two eye-related biotechs went public last week (PFNX and OCUL) and now trade below their IPO prices after pricing below the range. Another eye biotech IPO, Avalanche Biotechnologies ( AAVL ), increased its range and is expected to price Wednesday night.

The Waltham, MA-based company, which was founded in 2004, plans to list on the NASDAQ under the symbol EYEG. EyeGate Pharmaceuticals initially filed confidentially on May 14, 2014. Aegis Capital is the sole bookrunner on the deal. No pricing terms were disclosed.




The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: News Headlines , IPOs

Referenced Stocks: AAVL

Renaissance Capital

Renaissance Capital

More from Renaissance Capital:

Related Videos

Stocks

Referenced

100%

Most Active by Volume

33,110,376
  • $113.99 ▲ 1.77%
25,034,179
    $17.98 unch
24,486,872
  • $7.41 ▲ 2.07%
20,864,535
  • $7.39 ▼ 2.76%
18,600,501
  • $8.30 ▼ 0.36%
17,530,211
  • $8.14 ▲ 3.17%
17,299,208
  • $93.79 ▲ 2.74%
14,669,760
  • $25.78 ▼ 0.19%
As of 12/26/2014, 04:15 PM


Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com